Ventoux Biosciences

Ventoux Biosciences

novel, first-line treatments for dupuytren's disease

About Us

Revolutionizing dupuytren's treatment

Ventoux Biosciences is working to transform treatment for Dupuytren’s disease. Founded by a Dupuytren’s patient and propelled by a team with expertise from bench to bedside – we are driven to advance treatment options for Dupuytren’s and related immune-fibrotic diseases with significant unmet need.

We are working to advance VEN-201, our lead compound, based upon positive anti-fibrotic effects and a positive safety profile in pre-clinical research.
Play Video

Founder Story: Inspired by Patients, Powered by Purpose

Our founder has had Dupuytren’s and Ledderhose disease for about 15 years and his father has had it for over 30 years. Kurt Harrington started Ventoux Biosciences to embrace the challenges this disease presents and to seek novel, first-line, disease slowing treatment for millions of fellow patients and future generations faced with this debilitating, chronic, and progressive disease.


Kurt Harrington

CEO and Founder

Kurt is an experienced pharmaceutical executive and a Dupuytren’s and Ledderhose patient. He formed Ventoux Biosciences to help address the significant unmet medical need in Dupuytren’s Disease – a common, disabling, fibroproliferative hand disease with few treatment options. 

Kurt is an accomplished leader with over 25 years of Biopharmaceutical experience. Prior to starting Ventoux Biosciences, Kurt served as a consultant and advisor supporting leadership, founders, and operators ranging from large-cap multinational companies to early stage start ups on commercialization, corporate strategy, business development, market access and product development. Kurt served in various positions of increasing responsibility at AstraZeneca, Biogen, Amylin (acquired by BMS), Cadence Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals), and Avanir (acquired by Otsuka Pharmaceutical).  

Kurt received his M.B.A. in Pharmaceutical Marketing from Saint Joseph’s University and B.S. in Marketing from Western Michigan University. 

Ken Lipson, Ph.D.

Chief Scientific Officer and Vice President Corporate Strategy

Dr. Lipson has more than 30 years of experience in biotechnology and multinational pharmaceutical companies, including FibroGen, 3M Pharmaceuticals, Pharmacia, SUGEN and CIBA-Geigy (now Novartis).  Most of his career has focused on discovery and research of drugs for treatment of fibrosis and cancer, during which he made key contributions to several agents that are marketed or are currently in development. Dr. Lipson received awards from two of the companies at which he worked for his seminal contributions. In addition to the fibrosis and oncology therapeutic areas, he also has experience in cardiovascular, neuromuscular, inflammation, metabolic and infectious diseases, which are represented in his more than 100 publications in peer-reviewed journals, review articles and book chapters, and patent applications. 

Prior to his industry experience, Dr. Lipson served on the faculty of the department of Pathology at Temple University Medical School.  Dr. Lipson earned two simultaneous BS degrees in Biology and Chemistry from the University of Toledo, and a Ph.D. in Chemistry from Case Western Reserve University.  His postdoctoral studies at Sloan-Kettering Institute and Temple University Medical School provided additional training in biochemistry, pharmacology, cell biology and molecular biology.

Ventoux Biosciences

Scientific advisory board

Our Scientific Advisory Board provides expert guidance on clinical development, product development, and clinical optimization of the Ventoux Biosciences pipeline. A pipeline dedicated to advancing treatment options for patients with Dupuytren’s, Ledderhose, and other chronic, progressive, fibrotic diseases.

Dr. daiva bajorunas

Daiva Bajorunas MD is an endocrinologist with more than 25 years of experience in the biopharmaceutical industry.

Dr. Keith Denkler

Dr. Denkler is an accomplished, board certified plastic surgeon with expertise in aesthetic and reconstructive surgery.

Latha Satish,M.Sc, M.Phil, Ph.D

Dr. Satish is a trained biotechnologist with several years of experience in cell and molecular biology.

Dupuytren's disease

Dupuytren's Disease (Palmar Fibromatosis)

A Chronic, Progressive, Debilitating, Irreversible Disease

Dupuytren’s disease is a fibrotic disease that impacts the connective tissue of the hands and can lead to pain and disability.  Dupuytren’s is frequently under-treated due to few and predominantly surgical treatment options.
Dupuytren's Contracture

How Does Dupuytren's Impact Patients

Decreased / Loss of Hand Function

Disease causes fingers to bend inwards towards the palm. Affected fingers can not straighten, thus significant impact on hand function.

Loss of Hand Mobility

Fibrosis from Dupuytren's may also move laterally across the palm, impacting ability to spread hand / fingers.

Activities of Daily Living

Typically simple activities can be difficult or impossible for Dupuytren's patients - from shaking hands to putting on gloves or throwing a football.

Reduced Quality of Life (QoL)

Dupuytren's disease affects both performance of activities and patient QoL.

Work Loss / Economic Implications

Loss of hand function / range or hand motion are key limiters for some patients to perform work tasks.

Other Symptoms

Patients with Dupuytren's may also experience pain, tenderness, burning, pressure / tension, tightness, and itching.

Significant unmet Medical need & Large addressable population

>40 million

Estimated Prevalence in United States and Europe

Up to 85%

Post Operative Disease Recurrence


Approved first-line, disease modifying pharmacologic treatment options


Powered by purpose

a pipeline inspired by patients

We are targeting under-served, localized fibrotic diseases that are chronic, progressive, and debilitating. Our focus with our lead investigational compound VEN-201 is on addressing the significant unmet medical need that remains with Dupuytren’s Disease and Ledderhose Disease.


VEN-201, an investigational compound, demonstrated key anti-fibrotic actions and a positive safety profile in a pre-clinical in vivo study using an established dermal fibrosis (scleroderma) model. Based on the demonstrated anti-fibrotic effects we are working to advance VEN-201 as our lead developmental candidate targeting Dupuytren’s and Ledderhose disease. 

The investigational products listed on this page are not approved by the FDA or have not been approved for the above referenced indication, and the safety and effectiveness of such has not been established.
VEN-201 was initially identified via targeted scientific evaluation, expert opinion, and leveraging articifial intelligence data. Our goal was to identify previously approved treatments that have new potential as anti-fibrotic treatments for Dupuytren’s disease. The reference compound for VEN-201 has been previously approved by the FDA and EMEA for use in other indications for over 20 years, with a proven safety profile. Based upon our pre-clinical evaluation of VEN-201 as a potential anti-fibrotic agent, we are working to advance the compound as a repurposed, reformulated, disease modifying agent with a novel route of administration – via an expedited regulatory pathway.


About Us

Ventoux Biosciences, Inc. is a pioneering pre-clinical stage biopharmaceutical company, dedicated to revolutionizing the treatment of Dupuytren's disease (palmar fibromatosis). Founded in October 2022 by a patient impacted by Dupuytren's - our mission is to identify, test, and deliver first-line pharmacologic treatments aimed at delaying disease progression and improving post-operative outcomes. Our team is comprised of seasoned fibrosis and oncology drug discoverers, award winning Dupuytren's researchers, clinical development and regulatory leaders, and esteemed Dupuytren's treatment specialists. We are committed to swiftly expanding treatment options for individuals afflicted with this under-served, immuno-fibrotic, disease.

why invest

Ventoux Biosciences is committed to maximizing investor value by developing novel treatments for under-served fibrotic diseases with focus on Dupuytren's disease - a common, chronic, and progressive disease with no pharmacologic approved first-line options to delay disease progression and no cure.
Estimated Patients with Dupuytren's Disease
Prevalance of Rheumatoid Arthritis
> x
Increase in Patients Treated (1998-2011)
> %
VEN-201 Represents a Potential Novel, First-Line Tx Option
10 st

HOw to Invest

We are pleased to offer two different ways to invest in Ventoux Biosciences. Whether you are an experienced investor or first time investor, you can support our mission to revolutionize treatment for Dupuytren's disease. Please see below for additional information.

Major Investors

If you are interested in potential investment’s of $25k and above, please use the button below to set up a meeting.

Retail Investors

If you are interested in investing $100 and above, please use the button below to visit our community equity fundraising site.

We'd Love To Hear From You

contact us


315 S. Coast Highway 101 Suite U245 Encinitas, CA

Investor Relations

Subscribe today for company updates & Dupuytren's information

Latha Satish, M.Sc., M.Phil, Ph.D.

Dr. Satish is a trained biotechnologist with several years of experience in cell and molecular biology. Dr. Satish’s interest has been in skin research with a special focus on skin inflammation, infection, and fibrosis. The other arm of Dr. Satish’s research has been to study the molecular determinants of palmar fascial disease, Dupuytren’s contracture.

Her long-term interest has been to develop therapeutic agents to help alleviate the pain and distress of patients with Dupuytren’s. Her studies on Dupuytren’s disease were funded by a private donor, which moved the research forward to study this disease in an animal model, which was not feasible earlier. Dr. Satish’s research on Dupuytren has identified small molecules that can be used as a target to intervene with the progression and development of the disease.

Dr. Satish received her Ph.D. from a prestigious institute in India and did her post-doctoral training at the University of Pittsburgh. Currently, Dr. Satish serves as a faculty at the Division of Asthma Research, Cincinnati Children’s Hospital; named as the top hospital in the US. At Cincinnati Children’s, Dr. Satish researches Atopic Dermatitis, a chronic inflammatory skin disease affecting children and adults. Dr. Satish has published over 50 articles in peer-reviewed journals, review articles and book chapters.

Dr. Keith Denkler

Dr. Denkler is an accomplished, board certified plastic surgeon with expertise in aesthetic and reconstructive surgery. Dr. Denkler is a clinical professor of plastic surgery at UCSF and has a private practice in Marin County.

He is internationally renowned for his use of multiple approaches in treating the debilitating and disabling effects of palmar fibromatosis (Dupuytren disease). Dr. Denkler is an expert in needle aponeurotomy (NA), a minimally invasive procedure that uses subcutaneous needles to release the contracture as well as use of subcutaneous injection of collagenase. He has treated over 10,000 Dupuytren’s fingers, authored >35 publications and book chapters, presented internationally and domestically and is often cited for expert opinion in national and international news discussing Dupuytren’s. HIs pioneering investigational work documenting the safety of epinephrine with local anesthesia contributed to the origination of “wide-awake hand surgery”.

Dr. Denkler trained at prestigious medical institutions in the United States and Europe. He attended Baylor College of Medicine in Houston, Texas, followed by residency training in plastic and reconstructive surgery with the Cronin, Bauer, and Biggs group, also in Houston. Additionally, Dr. Denkler completed a hand surgery fellowship with Dr. Eugene Kilgore in San Francisco and one year of fellowship training in craniofacial surgery with Dr. Paul Tessier in Paris, France.

Dr. daiva bajorunas

Daiva Bajorunas MD is an endocrinologist with more than 25 years of experience in the biopharmaceutical industry.  She has a strong interest in advancing therapeutic options for conditions of significant unmet medical need. 

For the past decade, Daiva has been engaged as a consultant to the pharmaceutical industry, currently as Founder and Principal, DBMD Consulting, and previously as Chief Medical Officer / Chief Scientific Officer for Vault Bioventures. She has provided her expertise to enhance large, mid-size and small pharmaceutical company product development, clinical/regulatory, and life cycle strategies for both drugs and devices, including oral, transdermal, injectable and inhalative delivery systems, working across multiple therapeutic areas and geographies. She has considerable experience chairing Data Safety Monitoring Boards.   

In the past she held various R&D positions of increasing responsibility at Rhone-Poulenc Rorer, BMS, Aventis (acquired by Sanofi), and Kos Pharmaceuticals (acquired by Abbott). Before she joined industry, she held academic appointments at Memorial Sloan-Kettering Cancer Center and Cornell University Medical College (CUMC), and was Director of Clinical Care, Endocrinology Service, Memorial Hospital (MH), New York, NY. Daiva received her MD degree at the University of Michigan Medical School, did her residency training at St. Vincent’s Hospital & Medical Center in NY, her metabolism fellowship at Stanford University Medical Center, CA and her endocrinology fellowship at MH/CUMC, NY.